| Patient | Elvis Presley |
|---|---|
| Date of birth | 1987-01-08 |
| Identifiers | MRN HR-ML003-SYN; SSN (made up) 000-03-4417 |
| Document date | 2026-07-10 |
| Author | Coleman Ashby-Nakagawa, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
The patient attends this visit for establishing primary care for fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, with many prescribed drugs from several prescribers: a full medication reconciliation and prescription drug monitoring program review, a nonjudgmental substance use assessment, safety, and an addiction medicine referral. [S]
Hemoglobin: 15.1 g/dL; Sodium: 139 mmol/L; Potassium: 4 mmol/L; Creatinine: 1 mg/dL; eGFR (CKD-EPI 2021): 98 mL/min/1.73 m²; Glucose: 104 mg/dL (high); Hemoglobin A1c: 5.8% (high); ALT: 72 U/L (high); AST: 52 U/L (high); GGT: 78 U/L (high); TSH: 2.1 mIU/L; Urine albumin-to-creatinine ratio: 14 mg/g{creat}; PHQ-9: 8; GAD-7: 9; DAST-10: 7; AUDIT-C: 0. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-10 | Body height | 183 | cm | S |
| 2026-07-10 | Body weight | 109 | kg | S |
| 2026-07-10 | Body mass index (BMI) [Ratio] | 32.5 | kg/m2 | S |
| 2026-07-10 | Systolic blood pressure | 154 | mm[Hg] | S |
| 2026-07-10 | Diastolic blood pressure | 98 | mm[Hg] | S |
| 2026-07-10 | Heart rate | 94 | /min | S |
| 2026-07-10 | Respiratory rate | 16 | /min | S |
| 2026-07-10 | Body temperature | 36.8 | Cel | S |
| 2026-07-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-10 | Hemoglobin [Mass/volume] in Blood | 15.1 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 2026-07-10 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-07-10 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-10 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-07-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 98 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-10 | Glucose [Mass/volume] in Serum or Plasma | 104 | mg/dL | 70-99 mg/dL | High | S |
| 2026-07-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.8 | % | <=5.6% | High | S |
| 2026-07-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 72 | U/L | 7-55 U/L | High | S |
| 2026-07-10 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 52 | U/L | 8-48 U/L | High | S |
| 2026-07-10 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 78 | U/L | 8-61 U/L | High | S |
| 2026-07-10 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-07-10 | Albumin/Creatinine [Mass Ratio] in Urine | 14 | mg/g{creat} | <=29 mg/g{creat} | Normal | S |
| 2026-07-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-07-10 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | {score} | S | ||
| 2026-07-10 | Total score [DAST-10] | 7 | {score} | S | ||
| 2026-07-10 | Total score [AUDIT-C] | 0 | {score} | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultation | Up to five tablets a day; seven-day supply | Oral route | 2026-07-10 to 2026-07-17 | completed | S |
| Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultation | Up to three tablets a day; seven-day supply | Oral route | 2026-07-10 to 2026-07-17 | completed | S |
| Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a time | One tablet three times daily; seven-day supply | Oral route | 2026-07-10 to 2026-07-17 | completed | S |
| Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a time | Up to three tablets a day; seven-day supply | Oral route | 2026-07-10 to 2026-07-17 | completed | S |
| Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucoma | Stopped | Oral route | 2026-07-10 to 2026-07-10 | completed | S |
| Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist | One drop in each eye at bedtime | Ophthalmic route | 2026-07-10 | active | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag | One spray for a suspected overdose; call 911 | Nasal route | 2026-07-10 | active | S |
| Polyethylene glycol 3350, 17 g powder in a glass of water once daily | 17 g in water once daily | Oral route | 2026-07-10 | active | S |
| Senna 8.6 mg oral tablet, two tablets at bedtime | Two tablets at bedtime | Oral route | 2026-07-10 to 2026-08-07 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readings | active | confirmed | R53.83 | S — Synthetic presenting problem anchored to the documented prescribed drugs and weight gain; superseded when the consultation and tests made the diagnoses. |
| Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped working | active | confirmed | E66.811 | S — Synthetic modern diagnosis anchored to his documented weight gain. |
| Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoided | active | confirmed | H40.63X1 | S — Synthetic modern diagnosis anchored to his documented glaucoma and the retrospective interpretation of it as steroid-induced; not a claim about his real eyes. |